CO2024000221A2 - Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 - Google Patents

Pirimidinil-pirazoles sustituidos como inhibidores de cdk2

Info

Publication number
CO2024000221A2
CO2024000221A2 CONC2024/0000221A CO2024000221A CO2024000221A2 CO 2024000221 A2 CO2024000221 A2 CO 2024000221A2 CO 2024000221 A CO2024000221 A CO 2024000221A CO 2024000221 A2 CO2024000221 A2 CO 2024000221A2
Authority
CO
Colombia
Prior art keywords
pyrazoles
substituted pyrimidinyl
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
CONC2024/0000221A
Other languages
English (en)
Inventor
Philip D Ramsden
Jr Neil Bifulco
Natasja Brooijmans
Emanuele Perola
Richard Vargas
Steven Mark Wenglowsky
Douglas Wilson
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CO2024000221A2 publication Critical patent/CO2024000221A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona un compuesto representado por la fórmula estructural (I): (I) (I), o una sal farmacéuticamente aceptable de este útil para tratar el cáncer.
CONC2024/0000221A 2021-06-16 2024-01-12 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 CO2024000221A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211426P 2021-06-16 2021-06-16
US202263327474P 2022-04-05 2022-04-05
PCT/US2022/033576 WO2022266190A1 (en) 2021-06-16 2022-06-15 Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors

Publications (1)

Publication Number Publication Date
CO2024000221A2 true CO2024000221A2 (es) 2024-01-25

Family

ID=82694316

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0000221A CO2024000221A2 (es) 2021-06-16 2024-01-12 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2

Country Status (9)

Country Link
EP (1) EP4355742A1 (es)
KR (1) KR20240022609A (es)
AU (1) AU2022293861A1 (es)
BR (1) BR112023026538A2 (es)
CA (1) CA3224189A1 (es)
CO (1) CO2024000221A2 (es)
DO (1) DOP2023000277A (es)
IL (1) IL309013A (es)
WO (1) WO2022266190A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317574A (zh) 2021-06-28 2023-05-01 美商纜圖藥品公司 Ｃｄｋ２抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149469A1 (en) * 2004-01-09 2009-06-11 Carlos Garcia-Echeverria Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
CN108024970B (zh) * 2015-06-04 2021-10-01 奥瑞基尼探索技术有限公司 用作cdk抑制剂的经过取代的杂环衍生物
US11919904B2 (en) * 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors

Also Published As

Publication number Publication date
KR20240022609A (ko) 2024-02-20
CA3224189A1 (en) 2022-12-22
EP4355742A1 (en) 2024-04-24
BR112023026538A2 (pt) 2024-03-05
AU2022293861A1 (en) 2024-01-04
DOP2023000277A (es) 2024-03-28
WO2022266190A1 (en) 2022-12-22
IL309013A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
CO2022010317A2 (es) Inhibidores de egfr
CO2021016504A2 (es) Inhibidores de cdk
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2019004034A2 (es) Compuesto de piridina
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
CO2020014586A2 (es) Compuestos
UY38057A (es) Inhibidores de sarcómero cardíaco
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
ECSP20029790A (es) Compuestos moduladores de sting y métodos de elaboración y uso
ECSP11010880A (es) Compuestos orgánicos
CR20110492A (es) Compuestos tetracíclicos
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
DOP2023000280A (es) Inhibidores de cdk2
BR112021025491A2 (pt) Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
MX2021011753A (es) Degradadores de moleculas peque?as de stat3.
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
CO2021017202A2 (es) Compuestos tricíclicos
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
UY39662A (es) Inhibidores de egfr